Zhifeng Chen

State Key Laboratory Of Drug Research, 555 Zuchongzhi Road
Shanghai, 201203, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Deciphering the functional landscape of phosphosites with deep neural network.

Deciphering the functional landscape of phosphosites with deep neural network.

Journal: Cell reports
Published: May 19, 2023

The discovery of a non-competitive GOT1 inhibitor, hydralazine hydrochloride, via a coupling reaction-based high-throughput screening assay.

The discovery of a non-competitive GOT1 inhibitor, hydralazine hydrochloride, via a coupling reaction-based high-throughput screening assay.

Journal: Bioorganic & medicinal chemistry letters
Published: April 13, 2022

Inhibition of Autophagy by a Small Molecule through Covalent Modification of the LC3 Protein.

Inhibition of Autophagy by a Small Molecule through Covalent Modification of the LC3 Protein.

Journal: Angewandte Chemie (International ed. in English)
Published: July 16, 2021

Discovery of 8-Methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one Derivatives as Highly Potent and Selective Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitors.

Discovery of 8-Methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one Derivatives as Highly Potent and Selective Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitors.

Journal: Journal of medicinal chemistry
Published: March 27, 2020

Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors.

Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors.

Journal: Journal of medicinal chemistry
Published: January 08, 2020

PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.

PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.

Journal: Theranostics
Published: November 21, 2019

17‑AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA‑MB‑231 breast cancer cells.

17‑AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA‑MB‑231 breast cancer cells.

Journal: Oncology reports
Published: June 11, 2019

[Corrigendum] 17‑AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA‑MB‑231 breast cancer cells.

[Corrigendum] 17‑AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA‑MB‑231 breast cancer cells.

Journal: Oncology reports
Published: June 11, 2019

Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: Design, synthesis and biological evaluation.

Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: Design, synthesis and biological evaluation.

Journal: European journal of medicinal chemistry
Published: September 17, 2018

Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors.

Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors.

Journal: Bioorganic & medicinal chemistry
Published: June 22, 2018

Development and evaluation of a novel series of Nitroxoline-derived BET inhibitors with antitumor activity in renal cell carcinoma.

Development and evaluation of a novel series of Nitroxoline-derived BET inhibitors with antitumor activity in renal cell carcinoma.

Journal: Oncogenesis
Published: March 06, 2018

Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues.

Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues.

Journal: Organic & biomolecular chemistry
Published: November 01, 2017
Showing 1-12 of 17

Last Updated: 09/26/2026